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Abstract
Introduction: Breast cancers frequently metastasise to the skeleton where they cause osteolytic bone destruction
by stimulating osteoclasts to resorb bone and by preventing osteoblasts from producing new bone. The Runt-
related transcription factor 2, Runx2, is an important determinant of bone metastasis in breast cancer. Runx2 is
known to mediate activation of osteoclast activity and inhibition of osteoblast differentiation by metastatic breast
cancer cells. However, while Runx2-regulated genes that mediate osteoclast activation have been identified, how
Runx2 determines inhibition of osteoblasts is unknown.
Methods: The aim of this study was to determine how Runx2 mediates the ability of metastatic breast cancer cells
to modulate the activity of bone cells. We have previously demonstrated that Runx2 requires the co-activator core
binding factor beta (CBFb) to regulate gene expression in breast cancer cells. We, therefore, performed
independent microarray analyses to identify target genes whose expression is dependent upon both Runx2 and
CBFb. Common target genes, with a role in modulating bone-cell function, were confirmed using a combination of
siRNA, quantitative reverse transcriptase PCR (qRT-PCR), ELISA, promoter reporter analysis, Electrophoretic Mobility
Shift Assay (EMSA) and chromatin immunoprecipitation (ChIP) assays. The function of Runx2/CBFb-regulated genes
in mediating the ability of MDA-MB-231 to inhibit osteoblast differentiation was subsequently established in
primary bone marrow stromal cell cultures and MC-3T3 osteoblast cells.
Results: We show that Runx2/CBFb mediates inhibition of osteoblast differentiation by MDA-MB-231 cells through
induction of the Wnt signaling antagonist, sclerostin. We demonstrate that MDA-MB-231 cells secrete sclerostin and
that sclerostin-expression is critically dependent on both Runx2 and CBFb. We also identified the osteoclast
activators IL-11 and granulocyte-macrophage colony-stimulating factor (GM-CSF) as new target genes of Runx2/
CBFb in metastatic breast cancer cells.
Conclusions: This study demonstrates that Runx2 and CBFb are required for the expression of genes that mediate
the ability of metastatic breast cancer cells to directly modulate both osteoclast and osteoblast function. We also
show that Runx2-dependent inhibition of osteoblast differentiation by breast cancer cells is mediated through the
Wnt antagonist, sclerostin.
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Breast cancer bone metastases cause osteolytic bone
destruction by interrupting the normal bone remodelling
process [1-3]. These metastatic tumours interfere with
normal bone remodelling by stimulating osteoclasts to
resorb bone and preventing new bone growth by inhibit-
ing osteoblasts. Thus, bone degradation is due to both
increased activation of osteoclasts and suppression of
osteoblasts. Existing drug therapies primarily target the
osteoclasts to prevent bone resorption [4]. However,
w h i l et h i sa p p r o a c hr e d u c e st h eb o n el e s i o n sa n d
improves the quality of patient life, therapies that
restore osteoblast activity are required to achieve more
complete repair of osteolytic lesions [1]. It is well estab-
lished that breast cancer cells induce osteolytic lesions
by secreting soluble factors that lead to osteoclast-
mediated bone resorption. Such factors include osteo-
pontin, parathyroid hormone-related protein (PTHrP),
IL-11, IL-8, receptor activator of nuclear factor kappa-B
ligand (RANKL) and GM-CSF, all of which stimulate
osteoclasts either directly or indirectly [3]. In contrast,
few studies have identified mechanisms by which breast
cancer cells suppress bone synthesis by osteoblasts.
Breast cancer cells secrete Dickkopf-related protein 1
(DKK1), an antagonist of the Wnt/b-catenin pathway
that blocks osteoblast differentiation [5]. Members of
the transforming growth factor beta (TGFb)f a m i l ya l s o
contribute to inhibition of osteoblast differentiation by
metastatic breast cancer cells [6,7].
The Runt-related transcription factor 2, Runx2, is a
master-regulator of bone development and an important
determinant of bone metastasis in breast cancer cells
[8-10]. In breast cancers, Runx2 is aberrantly expressed
and inhibition of Runx2 function in metastatic breast
cancer cells transplanted to bone prevents the formation
of osteolytic lesions [8]. Runx2 contains a conserved
DNA-binding domain, termed the Runt domain, that
recognises the consensus sequence ACC(A/G)CA [11].
The Runt domain also interacts with its co-activator
core binding factor beta (CBFb). CBFb stimulates DNA-
binding of the Runt domain, and is essential for most of
the known functions of Runx2, including activation of
Runx2-regulated genes in breast cancer cells [12,13].
Runx2 contributes to the ability of breast cancer cells
to activate osteoclasts by up-regulating the expression of
Indian Hedgehog (IHH) [14]. IHH subsequently stimu-
lates PTHrP-induced RANKL production by osteoblasts,
which in turn activates osteoclasts [15,16]. Runx2 also
regulates expression of osteopontin (OPN), which binds
to the CD44 receptor to activate osteoclasts [15,16]. Pre-
vious reports showed that Runx2 expression in meta-
static breast cancer cells, and in prostate cancer cells,
also contributes to their ability to inhibit osteoblast
differentiation [8,17]. However, the molecular mechan-
ism by which Runx2 mediates osteoblast inhibition
remains unknown. The aim of this study was to identify
genes regulated by Runx2/CBFb that contribute to the
ability of metastatic breast cancer cells to modulate the
activity of bone cells. Since we had previously estab-
lished that CBFb contributed to the function of Runx2
in MDA-MB-231 cells we reasoned that independent
microarray analyses would identify the Runx2/CBFb-
regulated genes [18]. This analysis identified the osteo-
clastogenic cytokines IL-11 and granulocyte-macrophage
colony-stimulating factor (GM-CSF) as new Runx2/
CBFb targets in breast cancer cells. We also show that
Runx2/CBFb regulates expression of the Wnt antagonist
sclerostin and thus reveal a mechanism by which Runx2
mediates osteoblast inhibition by breast cancer cells.
Materials and methods
Cells and culture conditions
Human non-metastatic MCF7 cells and metastatic
MDA-MB-231 cells were obtained from ATCC and cul-
tured as previously described [18]. Mouse pre-osteoblas-
tic cells (MC3T3-E1) were obtained from ATCC and
cultured in a-MEM plus 10% FBS and 1% P/S. For dif-
ferentiation studies, MC3T3-E1 cells were cultured in
differentiation media containing 10 mM b-glycerol
phosphate (Sigma, St. Louis, MO, USA) and 50 μg/ml
L-ascorbic acid (Sigma). Conditioned medium from
MDA-MB-231 cells was collected as previously
described [6]. Depletion of sclerostin from the condi-
tioned media was carried out incubating the media with
4 μg of the sclerostin (Ab63097, Abcam, Cambridge,
UK) or Flag antibody (F1804, Sigma) per ml of media
followed by incubation with Protein G agarose beads.
Centrifuged beads were removed and the media was
used for the experiments. MC3T3-E1 cells were cultured
with conditioned medium or sclerostin-free conditioned
media according to reported protocol [6]. Cells were dif-
ferentiated for 18 days and then used either for alizarin
red staining or total mRNA extraction. Alizarin was
quantified from plates after elution following acetic acid
protocol as previously reported [19]. Absorbance was
measured at 405 nm and relative absorbance was
obtained (Abs/Abs Non-diff). One-way analysis of var-
iance was used to determine statistical differences
between groups using SPSS software (Chicago, IL, USA).
A P-value < 0.05 was considered statistically significant.
Multiple comparisons between individual groups were
assessed by the method of Tukey. Mouse bone marrow
stromal cells (BMSCs) were extracted as previously
described [20]. Mice were bred in a designated establish-
ment, in accordance with the Animals (Scientific Proce-
dures) Act 1986, at the University of Manchester
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harvesting of BMSCs. These procedures do not require
Institutional Ethics Board approval since they fall out-
side the Animals (Scientific Procedures) Act 1986. Cells
were then seeded into six-well plates, 5.6 × 10
6 cells/
well (Day 0). After 48 hours the growth medium was
changed to differentiation media and treated as the
MC3T3-E1 cells.
Microarrays
For each microarray analysis, MDA-MB-231 cells were
transfected with siRNAs. In total, three independent
replicates treated with siRNA against Runx2, CBFb or a
non-specific (siNS) were employed. Total RNA was
extracted using RNeasy Mini Kit (Qiagen GmbH, Hil-
den, Germany) according to the manufacturer’s instruc-
tions. The quality and size distribution of the RNA were
assessed with the RNA Nano Labchip kit (Agilent Tech-
nologies, Waldbronn, Germany). Samples were hybri-
dised with the Human Genome U133 Plus 2.0 Array,
according to the manufacturer’s instructions (Affyme-
trix, Santa Clara, CA, USA). Each microarray was per-
formed in triplicate for statistical robustness. Technical
quality control was performed with dChip (V2005) using
the default settings [21,22]. Background correction,
quantile normalisation and gene expression analysis
were performed using RMA in Bioconductor [23]. Prin-
cipal component analysis (PCA) was performed with
Partek Genomics Solution (version 6.5, Copyright 2010,
Partek Inc., St. Charles, MO, USA). Differential expres-
sion analysis was performed using Limma using the
functions lmFit and eBayes [24]. Gene lists of differen-
tially expressed genes were controlled for false discovery
rate (fdr) errors using the method of QVALUE [25].
The microarray data were deposited via ArrayExpress
with the accession number: E-MEXP-3230.
Transient transfection and siRNAs
For the MCF-7 transfections of Runx2, the plasmid
pRK-Flag-Cbfa1 containing the wild-type Runx2 protein
or the parent plasmid was used [9]. Transfections were
performed using lipofectamine 2000 (Invitrogen, Carls-
bad, CA, USA). MDA-MB-231 cells transfected with
human siRNA against CBFb (siCBFb), Runx2 (siRunx2),
or a non-specific siRNA (siNS) (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, USA), were performed with
oligofectamine (Invitrogen).
Generation of stable MDA-MB-231 cell lines
Cell lines were established using short hairpin (sh) RNA
lentiviral particles for human CBFb,R u n x 2o rc o n t r o l
with a non specific shRNA according to the suppliers
instructions (Santa Cruz Biotechnology, Inc.). Stable cell
lines expressing the shRNA were selected by the
addition of 1 μg/ml puromycin. Clones were assessed
for the expression of CBFb or Runx2 by Western blot.
Luciferase assays
The human SOST promoter (SOST WT) in pGL3B plas-
mid encoding the wild-type promoter sequence (2 kb
upstream of the 5’-UTR) has been described previously
[26]. The mutant SOST promoter reporter (SOST Mut)
was generated by site directed mutagenesis (Stratagene,
La Jolla, CA, USA), changing the three consensus
Runx2-binding sites, ACCACA, to ATGACA. The
human GM-CSF promoter/enhancer (CSF-2 WT) repor-
ter plasmid and the plasmid with the Runx2 sites
mutated in the promoter and the enhancer (CSF-2 Mut)
has been described previously [27]. Luciferase assays
were performed as described previously [9].
ChIP assays
ChIP assays were performed as described previously [18].
Real time PCR was performed with SOST promoter pri-
mers (forward: 5’-AAGCCGGAGCTCATTTTGATA-3’;
reverse: 5’-CCTCCCCAAAGACTTCTCCTC-3’); CSF-2
promoter primers (forward: 5’-GTTCCCATGTGTGGCT-
GATAAG-3’ reverse: 5’-TCTGTGTACTGGGCT-
CACTGG-3’) and 18S gene primers (forward: 5’-
GTAACCCGTTGAACCCCATT-3’ reverse: 5’-CCATC-
CAATCGGTAGTAGCG-3’).
ELISA assays
MDA-MB-231 cells were transfected with siRunx2 or
siNS and after 48 h ELISA were performed to measure
the amount of sclerostin and GM-CSF in the media.
Immuno-detection was performed using ELISA assay
kits BI-20492 (Biomedica Gruppe, Vienna, Austria) and
DGM00 (R&D Systems, Minneapolis, MN, USA) respec-
tively. Data are presented as mean ± standard deviation
(SD).
RT-PCR
Total mRNA was isolated from cell pellets using an
RNeasy mini kit (Qiagen); genomic DNA was removed
using the RNase-free DNase set (Qiagen). mRNA
expression of the selected genes was determined by real-
time PCR using one-step QuantiTect SYBR Green RT-
PCR kit (Qiagen) according to the manufacturer’s proto-
col. Nucleotide sequences of specific primers for the dif-
ferent human genes can be supplied on request. Data
were analysed as described previously [18]. For compari-
son of mRNA levels, the data were analyzed using the
equation described by Livak [28].
Immunofluorescence
Cells grown on coverslips were fixed with 4% parafor-
maldehyde, permeabilised with 0.1% Triton X-100, and
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buffered saline. Signals were detected by an indirect
immunofluorescence technique using primary antibodies
with a mouse monoclonal anti-Runx2 (D130-3, MBL
International) or rabbit polyclonal anti-CBFb antibodies
(Ab33516, Abcam) and Alexa fluor secondary antibodies
(A11005 and A11008, Invitrogen). Images were pro-
cessed using MacBiophotonics ImageJ (Bethesda, Mary-
land, USA).
Western blot
Proteins were detected with a mouse monoclonal anti-
Runx2 (MBL International) or rabbit polyclonal anti-
CBFb antibody (Abcam). Goat anti-mouse IgG conju-
gated with horseradish peroxidase (Pierce, Rockford, IL,
USA), was used as a secondary antibody. Immune com-
plexes were detected by Supersignal West Dura
Extended Duration Substrate according to the manufac-
turers’ protocol (Pierce).
Electrophoretic Mobility Shift Assay (EMSA)
EMSAs were performed as described previously [9]. The
DNA sequence of the oligonucleotides used were as fol-
lows: SOST, sense 5’CAGTTCTGAAAACCACA
GCCGCCA3’,a n t i s e n s e5 ’CAGTTGGCGGCTGTGG
TTTTCAGA3’; CSF-2,s e n s e5 ’CAGTGGCATTTTG
TGGTCACCATT3’,a n t i s e n s e5 ’CAGTAATGGTGAC-
CACAAAATGCC3’;S O S TM u t ,s e n s e5 ’CAGTTCT-
GAAACAGTCAGCCGCCA3’,a n t i s e n s e5 ’CAGTTGGC
GGCTGACTGTTTCAGA3’; CSF-2 Mut, sense 5’CAG
TGGCATTTATTGTGCATCATT3’,a n t i s e n s e5 ’CAG
TAATGATGCACAATAAATGCC3’.
Results
Runx2 and CBFb in metastatic breast cancer cells regulate
activators of osteoclasts and inhibitors of osteoblasts
Given that Runx2 is required for the formation of osteo-
lytic metastases we sought to identify target genes that
mediate this process. The breast cancer cell line, MDA-
MB-231, forms osteolytic bone lesions in mice, and
Runx2 is required for this process [8,27]. We have pre-
viously shown that Runx2 requires its co-activator,
CBFb, to regulate gene expression in MDA-MB-231
cells [18]. These proteins also co-localise in the nucleus
of MDA-MB-231 cells (Figure 1A). To identify Runx2/
CBFb target genes that might be involved in bone
metastases, we performed independent microarray ana-
lyses using mRNA derived from MDA-MB-231 cells
transfected with either siRunx2 or siCBFb (Figure 1B).
Cells transfected with non-specific siRNA (siNS) were
used as controls. Transfection of Runx2 siRNAs reduced
Runx2 expression by approximately 80% compared to
siRNA controls, whereas CBFb was undetectable in cells
transfected with CBFb siRNA (Figure 1B). Three
independent biological samples for each condition were
used for array hybridizations. Hybridizations were per-
formed for each of the samples using the Human Gen-
ome U133 Plus 2.0 Array. Of the 38,500 genes on the
microarrays, we identified 357 genes in the siRunx2-
transfected cells and 340 in the siCBFb-transfected cells,
whose expression changed by ≥ 2-fold. The data are pre-
sented as a volcano plot (Figure 1C). Genes whose
expression changed significantly by ≥ 2-fold (q-value <
0.05) are located in the upper-left and upper-right quad-
rants of the plot. Hierarchical clustering analysis of
these genes was employed to characterize the expression
patterns in the three conditions (Figure 1D). Distinct
patterns of expression differences were observed for
Runx2 and CBFb samples compared to NS.
A comparison of genes whose expression changed in
the Runx2 and CBFb knockdown cells revealed 161
common genes (Figure 2A; Additional file 1). A change
in expression of a selection of these genes was subse-
quently verified using qRT-PCR. All genes tested by
qRT-PCR displayed significant changes in expression in
both the Runx2 and CBFb knockdown cells (Figure 2B).
No significant reduction in Runx2 expression was
observed in siCBFb-transfected cells, nor was there a
significant reduction in CBFb expression in siRunx2-
transfected cells, indicating that changes in expression
are not due to downstream reciprocal changes in Runx2
or CBFb expression. From the 161 common genes, 86
were down-regulated and, therefore, are potentially acti-
vated by Runx2/CBFb. These genes were subjected to
gene ontology analysis using the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID)
analysis online tool (Additional file 2 Table S1) [29].
This analysis identifed a number of genes that encode
secreted proteins. Within this group we identifed three
genes encoding soluble ligands with established roles in
bone-related processes, IL-11, CSF-2 and SOST.I L - 1 1
and GM-CSF (encoded by CSF-2) are osteoclastogenic
cytokines whose expression by metastatic breast cancer
cells is known to stimulate bone resorption by osteo-
clasts [30,31]. In contrast, SOST encodes an inhibitor of
bone formation, the Wnt antagonist sclerostin [32].
Sclerostin is normally secreted by osteocytes to inhibit
osteoblast differentiation. However, it has not previously
been implicated in breast cancer bone metastasis.
Runx2 directly regulates expression of SOST and CSF-2
genes in MDA-MB-231 cells
Previous studies have shown that Runx factors directly
regulate SOST and CSF-2 expression in other cell-types
but they are not known targets of Runx2 in breast can-
cer cells [27,33]. We, therefore, focussed our analysis on
the regulation of SOST and CSF-2 by Runx2 in MDA-
MB-231 cells. We first demonstrated that expression of
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Page 4 of 14Figure 1 Independent microarray analyses identify new targets of Runx2 and CBFb in metastatic MDA-MB-231 cells. (A) Fluorescence
microscopy showing co-localization of Runx2 and CBFb in the nucleus of MDA-MB-231 cells. MDA-MB-231 cells were immunostained with
specific antibodies as indicated. Nuclei (blue) were stained with DAPI. (B) Western blot showing siRNA knockdown of Runx2 and CBFb. The
upper panel shows total cell lysates derived from siRNA transfections of MDA-MB-231 cells after immunodetection with anti-Runx2 or anti-CBFb
antibodies. The lower panel is a Tubulin loading control. (C) Volcano plots of differentially expressed genes in MDA-MB-231 cells treated with
siRNAs against Runx2 (siRunx2) or CBFb (siCBFb) vs non-specific siRNA control (siNS). The q values were plotted against fold suppression/
induction. The darker vertical line indicates a cut off of ≥ 2-fold change and the darker horizontal line represents a q value ≤ 0.05. Each point
represents an individual transcript. (D) Hierarchical clustering analysis. The colour bar indicates the relative abundance of each transcript with red
being the most abundant.
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MCF-7 breast cancer cells by heterologous expression of
Runx2 (Figure 3A). MCF-7 cells express CBFb but not
Runx2. Transfection of MCF-7 cells with a Runx2-
expression plasmid resulted in a significant increase in
SOST and CSF-2 mRNA, thus confirming that aberrant
expression of Runx2 can drive SOST and CSF-2 expres-
sion (Figure 3A). We also demonstrated that endogen-
ous Runx2 in MDA-MB-231 cells bind to the Runx sites
in both gene promoters (Figure 3B). Nuclear extracts
from MDA-MB-231 cells were used in EMSAs to
demonstrate specific binding of Runx2 to the promoter
regions (Figure 3C). Incubation of radiolabelled Runx2-
binding sites from SOST and CSF-2 promoters resulted
in specific complex formation that could be ablated by
specific competitor DNA but not by competitor DNA in
which the Runx site was mutated. The complex was also
supershifted by the addition of a Runx2 antibody. We
also performed ChIP experiments on chromatin derived
from MDA-MB-231 cells (Figure 3D). Both the SOST
Figure 2 Runx2 and CBFb are required for the expression of genes encoding the soluble ligands, IL-11, sclerostin and GM-CSF in
MDA-MB-231 cells. (A) Venn diagram showing the number of genes with ≥ 2-fold expression-change in each microarray. (B) Validation of
Runx2 and CBFb target genes. MDA-MB-231 cells transfected with siRunx2, siCBFb or a non-specific siRNA were subject to real-time qRT-PCR.
Acidic ribosomal phosphoprotein P0 (RPLO) mRNA was used as a control for normalization and relative values are shown. Data are presented as
mean ± standard deviation (SD) (n = 3). Statistical evaluation of significant differences was performed using the Student’s t-test. Asterisk (*)
indicates P < 0.05 when compared to control (siNS).
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Page 6 of 14Figure 3 Runx2 binds to the SOST and CSF-2 promoter. (A) Western blot showing Runx2 expression after transfection in non-metastatic
MCF-7 cells. MCF-7 cells were transfected with a Runx2-expression plasmid or the parent plasmid (-). The upper panel shows total cell lysates
derived from transfections of MCF-7 cells after immunodetection with an anti-Runx2 antibody. The lower panel is a Tubulin loading control. The
graphs show an increase in SOST and CSF-2 expression in non-metastatic MCF-7 cells after transfection with a Runx2-expression plasmid. (B)
Diagram showing the localization of the Runx2 binding sites in the human SOST and CSF-2 promoter. The arrow indicates the start of
transcription. (C) EMSA demonstrating specific binding of Runx2 to the Runx elements in the SOST and CSF-2 promoters. Nuclear extracts from
MDA-MB-231 were incubated with Runx-binding sites from the human SOST or CSF-2 gene promoters. Competition assays were performed with
a 100-fold molar excess of either cold wild-type (WT comp.) or mutant (Mut comp.) probes. Each gel is representative of three experiments. (D)
Runx2 is recruited to the SOST and CSF-2 promoter in MDA-MB-231 cells. ChIP assays using Runx2 antibodies. Data are presented as mean ±
standard deviation (S.D.) (n = 3). * indicates P < 0.05 compared with IgG by analysis of variance.
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pitated with Runx2 antibody as compared to a non-spe-
cific control IgG antibody.
To determine if Runx2 directly activates the SOST and
CSF-2 promoters, MDA-MB-231 cells were transfected
with siRunx2 or non-specific siRNA (siNS) followed by
transfection with a luciferase reporter plasmid contain-
ing the human SOST or CSF-2 promoters (Figure 4). In
the Runx2-knockdown cells the activity of both promo-
ters was significantly decreased compared to control
cells (Figure 4A, B). Moreover, mutation of the Runx2-
binding sites in either of the promoters resulted in
reduced promoter activity (Figure 4C, D).
To examine the effect of knocking down Runx2
expression in MDA-MB-231 cells on protein expression
ELISA was used to measure the amount of sclerostin
and GM-CSF secreted into the media (Figure 4E). Cells
transfected with siRunx2 produced approximately five-
fold less sclerostin than control cells. GM-CSF was
reduced by almost three-fold. Taken together these data
demonstrate that Runx2 is required for the production
of sclerostin and GM-CSF by activating expression of
the SOST and CSF-2 genes in MDA-MB-231 cells.
Thus, Runx2 regulates the expression of soluble protein
ligands that either stimulate osteoclast activity or inhibit
osteoblast differentiation.
Sclerostin mediates inhibition of osteoblast differentiation
by MDA-MB-231 cells
While the role of GM-CSF as an activator of osteoclasts
in breast cancer bone metastasis is well established, the
role of sclerostin has not been investigated [28]. Indeed,
very little is known about the mechanisms by which
metastatic breast cancer cells inhibit osteoblast differen-
tiation. Moreover, how Runx2 mediates osteoblast inhi-
bition has not been investigated. Our finding that
Runx2/CBFb drives SOST expression in MDA-MB-231
suggested that sclerostin secretion by MDA-MB-231
cells might determine their ability to inhibit osteoblast
differentiation.
Previous studies have shown that MDA-MB-231-con-
ditioned media inhibits the differentiation of osteoblast
precursors in bone marrow stromal cell cultures
(BMSCs) [34]. To determine if sclerostin expression by
MDA-MB-231 cells contributes to their ability to inhibit
differentiation of osteoblasts ,w e ,t h e r e f o r e ,e x a m i n e d
the effect of sclerostin-depleted MDA-MB-231-condi-
tioned media on osteoblast differentiation in BMSCs
(Figure 5A). Differentiation of BMSCs was induced by
the addition of ascorbic acid and b-glycerol phosphate
and assessed by the presence of calcium deposition with
alizarin red after 18 days. Alizarin red was quantified by
measuring absorbance at 405 nm after elution with
acetic acid (Figure 5B) [19]. Sclerostin was depleted in
MDA-MB-231-conditioned media by immunoprecipita-
tion with a sclerostin-specific antibody prior to addition
to the BMSC culture. Media treated with an anti-Flag
antibody was used in controls. As expected, in non-con-
ditioned differentiation media, significant alizarin red
staining was observed in BMSC cultures after 18 days
and no staining was observed in cultures grown in non-
differentiation media (Figure 5A, B). Also as expected,
differentiation of BMSCs was significantly inhibited
when grown in conditioned differentiation media
derived from MDA-MB-231 cells (Figure 5A, B). The
anti-Flag treated media also inhibited differentiation of
the BMSCs as observed with MDA-MB-231 conditioned
media (Figure 5A, B). In contrast, significant differentia-
tion was observed in BMSCs cultured in sclerostin-
depleted media (Figure 5A, B). In addition, qRT-PCR
demonstrated that expression of the osteoblast differen-
tiation marker, osteocalcin, was increased in BMSCs
grown in sclerostin-depleted media, but not in cells
g r o w ni nt h ea n t i - F l a gt r e a t e dm e d i a( F i g u r e5 B ) .W e
also performed the same experiments on the pre-osteo-
blast cell line MC3T3-E1, which can also be induced to
differentiate to mature calcium-depositing osteoblasts
(Figure 5C, D) [6]. As with the BMSC cultures, anti-Flag
treated media inhibited differentiation and osteocalcin
expression, whereas cells treated with sclerostin-depleted
media differentiated and osteocalcin expression
increased (Figure 5C, D). Thus, inhibition of osteoblast
differentiation by MDA-MB-231 is mediated by
sclerostin.
Runx2 expression in MDA-MB-231 cells is required for
inhibition of osteoblast differentiation
A previous study demonstrated that expression of a
dominant-negative form of Runx2 in MDA-MB-231 pre-
vented inhibition of osteoblasts in co-culture with
BMSCs [8]. We predicted that knockdown of Runx2
expression in MDA-MD-231 cells should permit osteo-
blast differentiation by MDA-MB-231-conditioned
media. We, therefore, examined the effect of knocking
down the expression of Runx2 on the ability of MDA-
MB-231-conditioned media to suppress osteoblast dif-
ferentiation. We generated stably transfected MDA-MB-
231 cells, in which either Runx2 (MDA-shRunx2 cells)
or CBFb (MDA-shCBFb cells) was knocked down by
shRNAs (Figure 6). In both cell lines sclerostin expres-
sion was significantly reduced compared to control cells
harbouring non-specific shRNA (MDA-shNS cells)
(Figure 6A). Thus, both transient and stable RNAi treat-
ments, independently targeting either Runx2 or CBFb,
resulted in down-regulation of sclerostin expression.
Taken together with the induction of sclerostin mRNA
by exogenous Runx2 in MCF-7 cells, it is unlikely that
the RNAi effects on sclerostin expression are due to off-
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Page 8 of 14Figure 4 Runx2 is essential for the expression of secreted sclerostin and GM-CSF in MDA-MB-231 cells. (A and B) Runx2 regulates the
activity of the SOST and CSF-2 promoter. MDA-MB-231 cells transfected with siRunx2 or a non-specific siRNA (siNS) were transfected with a
plasmid containing either the SOST (A) or CSF-2 (B) promoter. Luciferase activities are presented as mean values ± SD All values are relative to
the activity of the Renilla luciferase reporter. Insets show Western blots of Runx2 expression when transfected with siRNAs as indicated. (C and
D) MDA-MB-231 cells transfected with the luciferase reporter constructs containing, either the SOST (C) or CSF-2 (D) wild-type promoter (WT), or
the Runx site mutant (Mut). Data are presented as mean ± standard deviation (SD) (n = 3). All values are relative to the activity of the Renilla
luciferase reporter. (E) ELISA showing sclerostin and GM-CSF in the media of MDA-MB-231 cells. Data are presented as mean ± standard
deviation (SD) (n = 3). Statistical evaluation of significant differences was performed on all graphical data using the Student’s t-test. Asterisk (*)
indicates P < 0.05 when compared to controls.
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Page 9 of 14target effects of the RNAi. We conclude that sclerostin
expression is dependent on Runx2 and CBFb.
We next compared the effect of conditioned media
derived from MDA-shRunx2 cultures and control
MDA-shNS cultures on osteoblast differentiation in
BMSCs (Figure 6B, C). Differentiation was induced by
the addition of ascorbic acid and b-glycerol phosphate
and assessed by the presence of calcium deposition with
alizarin red after 18 days. Differentiation of BMSCs was
significantly inhibited when grown in conditioned differ-
entiation media derived from MDA-MB-231 cells stably
transfected with non-specific shRNA (MDA-shNS)
Figure 5 Sclerostin mediates inhibition of osteoblast differentiation by MDA-MB-231 cells. (A) Depletion of sclerostin from MDA-MB-231-
conditioned media permits osteoblast differentiation in primary bone marrow stromal cell cultures (BMSCs). BMSCs were differentiated with
normal differentiation media (Diff) or MDA-MB-231-conditioned media (MDA). Cells grown in non-differentiation media (Non-Diff) were used as
negative control. MDA-MB-231 media were depleted by immunoprecipitation with a sclerostin antibody (AbScl) or a control Flag antibody
(AbFlag) as indicated below the panels. (B) Alizarin red was quantified following elution and total RNAs from cells treated as in (A) were used to
analyse expression of the osteoblast differentiation marker, osteocalcin. Data are presented as mean ± standard deviation (SD) (n = 3). One-way
analysis of variance was used and multiple comparisons between individual groups were assessed by the method of Tukey. * indicates P < 0.05
compared to Non-Diff by analysis of variance; # indicates P < 0.05 compared to Diff+MDA+AbFlag by analysis of variance. (C) Sclerostin inhibits
the differentiation of the pre-osteoblastic cell line MC3T3-E1. MC3T3-E1 cells were treated as in (A). (D) Alizarin red and mRNA levels of
osteocalcin were determined. Data were analysed as in (B).
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Page 10 of 14(Figure 6B, C). In contrast, significant alizarin red stain-
ing was observed in BMSC cultures grown in condi-
tioned differentiation media derived from MDA-
shRunx2 cells (Figure 6B, C). Osteocalcin expression
was also increased in BMSCs grown in differentiation
media derived from MDA-shRunx2 cells compared to
BMSCs grown in differentiation media derived from
non-specific shRNA (MDA-shNS) (Figure 6C). Taken
together, our data show that Runx2 mediates inhibition
of osteoblast differentiation through induction of scler-
ostin secretion by MDA-MB-231 cells.
Figure 6 Runx2 expression in MDA-MB-231 cells is required for inhibition of osteoblast differentiation. (A) Western blot showing stable MDA-
MB-231 cells knocked down for Runx2 or CBFb. The left panel shows total cell lysates derived from stables MDA-MB-231 cells, transfected with a
shRNA non-specific (shNS) or shRNA for Runx2 (shRunx2) or CBFb (shCBFb). The lower panel is a Tubulin loading control. Graphs show that expression
SOST is significantly reduced in the cell lines. Data are presented as mean ± standard deviation (SD) (n = 3). Statistical evaluation of significant
differences was performed using the Student’s t-test. Asterisk (*) indicates P < 0.05 when compared to control (shNS). (B) Knock-down of Runx2 in
MDA-MB-231 cells permits the differentiation of osteoblasts. BMSCs were differentiated with normal differentiation media (Diff), conditioned media
from stable shNS cells (MDAshNS) or shRunx2 cells (MDAshRunx2). Cells grown in non-differentiation media (Non-diff) were used as negative control
of differentiation. (C) Alizarin red was quantified following elution and total RNAs from cells treated as in (B) were used to analyse expression of the
osteoblast differentiation marker, osteocalcin. Data are presented as mean ± standard deviation (SD) (n = 3). One-way analysis of variance was used
and multiple comparisons between individual groups were assessed by the method of Tukey. * indicates P < 0.05 compared to Non-Diff by analysis of
variance; # indicates P < 0.05 compared to Diff+MDA shNS by analysis of variance. (D) Diagram depicting the proposed role of Runx2 in the
modulation of bone cell functions by regulating secreted factors. Other genes involved in invasion are omitted for clarity.
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The aim of this study was to identify Runx2/CBFb-regu-
lated genes that contribute to the ability of metastatic
breast cancer cells to modulate the activity of bone cells.
To this end we established that Runx2/CBFb regulates
the expression of genes that mediate both the activation
of osteoclasts and the inhibition of osteoblasts by meta-
static breast cancer cells (Figure 6C).
W h i l em a n yo ft h eg e n e sw ei d e n t i f i e dh a v er o l e si na
range of cellular processes that might be important in
breast cancers, we focused on genes that have a role in
directly modulating bone-cell function. The secreted
ligands IL-11, CSF-2 and SOST were identified as Runx2/
CBFb-regulated genes in MDA-MB-231 cells. IL-11 is a
potent activator of osteoclast bone resorption [30]. Our
finding that Runx2/CBFb regulates IL-11 is supported by a
previous report, which showed that Runx2 up-regulated
IL-11 expression in chondrocytes [35]. However, we were
unable to identify any consensus Runx-binding sites within
the immediate vicinity of the IL-11 promoter. We are pre-
sently exploring possible mechanisms by which Runx2/
CBFb regulates IL-11 expression. Runx-binding sites are
present within the CSF-2 and SOST promoters and we
demonstrated that recruitment of Runx2 to these sites is
necessary for transcription [27,33]. CSF-2 is a known tar-
get gene of Runx1 in haematopoietic cells [27]. CSF-2
encodes the cytokine GM-CSF, which has previously been
shown to contribute to osteolytic bone metastasis of breast
cancer by stimulating osteoclasts [31]. Thus, our finding
that GM-CSF expression is regulated by Runx2 in MDA-
MB-231 cells suggests that Runx2 contributes to the for-
mation of osteolytic lesions in metastatic breast cancers, at
least in part, by driving the expression of GM-CSF. Pre-
vious work has shown that Runx2 contributes to the sti-
mulation of osteoclasts by activating expression of IHH
[14]. Runx2 also regulates expression of OPN, which acti-
vates osteoclasts [15,16]. We propose that in addition to
IHH and OPN, Runx2 mediates stimulation of osteoclast
activity by up-regulating the expression of the osteoclasto-
genic cytokines IL-11 and GM-CSF in metastatic breast
cancer cells (Figure 6C).
The most significant finding presented in this study is
our demonstration that Runx2 regulates sclerostin
expression to inhibit osteoblast differentiation. Sclerostin
inhibits osteoblastogenesis by antagonising Wnt signal-
ing [32,36]. In humans, loss-of-function mutations in
SOST cause sclerosteosis, a disorder in which excessive
bone growth occurs. The bones of these patients are
also more resistant to fracture. Sclerostin is ordinarily
secreted by osteocytes and binds to the co-receptors
LRP5 and LRP6 on the surface of osteoblasts to prevent
ligand-mediated Wnt signaling, and thus inhibit
osteoblast differentiation. Inhibition of osteoblast differ-
entiation is a feature of breast cancer tumour-induced
osteolysis. To-date only two factors have been impli-
cated in this process, TGF-b and the Wnt antagonist,
DKK1 [5,6]. TGF-b has a number of effects on bone
cells, one of which is the inhibition of osteoblast differ-
entiation. DKK1 is a secreted Wnt antagonist that inhi-
bits osteoblast differentiation in a similar way to
sclerostin. It has recently been shown that metastatic
breast cancer cells secrete DKK1 and that it contributes
to their ability to inhibit osteoblast differentiation in
vitro [5]. There is also evidence that its inhibitory effect
on osteoblasts promotes osteolytic metastases in multi-
ple myeloma-associated bone disease [37,38]. Thus, inhi-
bition of osteoblasts by Wnt signalling inhibitors can
contribute to the development of osteolytic bone lesions.
It is, therefore, likely that both sclerostin and DKK1
cooperate to inhibit Wnt signaling in osteolytic lesions
in breast cancer bone metastases. Further studies are,
therefore, required to determine if sclerostin contributes
to the development of bone metastases in vivo.
Existing therapies for bone metastases primarily target
the osteoclasts to prevent bone resorption. However,
complete healing of bone lesions is not achieved [1,39].
This is likely due, at least in part, to the inhibitory effect
of the metastatic tumour cells on osteoblast differentia-
tion and thus new bone synthesis. Therapies that restore
osteoblast activity are urgently needed to improve lesion
repair. Inhibiting sclerostin, secreted by bone metastases,
may prevent inhibition of osteoblast differentiation in
osteolytic lesions and thus improve healing. Inhibitors of
sclerostin are presently being developed to treat osteo-
porosis and fractures to increase bone density and aid
healing [40,41]. Our finding that metastatic breast can-
cer cells express sclerostin, therefore, suggests that
therapies to target sclerostin might also improve healing
of osteolytic lesions in breast cancer patients.
Conclusions
Runx2 and CBFb are required for the expression of genes
that mediate the ability of metastatic breast cancer cells
to directly modulate both osteoclast (GM-CSF, IL-11)
and osteoblast (sclerostin) function. Runx2-dependent
inhibition of osteoblast differentiation, by MDA-MB-231
cells, is mediated through the Wnt antagonist, sclerostin.
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